{'fraction_non_alphanumeric': 0.04207920792079208, 'fraction_numerical': 0.0165016501650165, 'mean_word_length': 5.284974093264249, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of triiodothyronine and tamoxifen on cell transformation induced by an activated c-Ha-ras oncogene.

We have found that the thyroid hormone 3,5',3'-triiodo-L-thyronine stimulates the transformation of Rat 6 fibroblasts when these cells are transfected with an activated human c-Ha-ras oncogene (T24). 3,5',3'-Triiodo-L-thyronine did not further augment the stimulation of oncogene-induced transformation obtained with a phorbol ester tumor promoter (12-O-tetradecanoylphorbol-13-acetate) or a factor from fetal calf serum. On the other hand, tamoxifen, an antiestrogen that also inhibits protein kinase C, markedly inhibited Ha-ras-induced cell transformation in the presence of 12-O-tetradecanoylphorbol-13-acetate or fetal calf serum. Time course studies and Southern blot analyses of DNAs isolated from transformed foci provided evidence that 3,5',3'-triiodo-L-thyronine and tamoxifen do not exert their effects simply by enhancing or inhibiting integration of the transfected oncogene into cellular DNA. These findings indicate that hormonal factors can modulate the ability of an activated Ha-ras oncogene to transform cells. They may be relevant to the process of multistage carcinogenesis in vivo.